Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Bicycle Therapeutics plc (BCYC) will be participating in key investor conferences in March 2024 to discuss its innovative therapeutics based on bicyclic peptide technology. The company will engage in fireside chats at TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays Global Healthcare Conference.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle^®) technology, today announced that management will participate in the following investor conferences in March:

• TD Cowen 44^th Annual Health Care Conference on Wednesday, March 6, 2024; fireside chat at 11:10 a.m. ET
• Leerink Partners Global Biopharma Conference on Monday, March 11, 2024; fireside chat at 12 p.m. ET
• Barclays 26^th Annual Global Healthcare Conference on Thursday, March 14, 2024; fireside chat at 8:30 a.m. ET

Live webcasts of the fireside chats will be accessible in the Investor section of the company’s website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available following the fireside chat dates.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle^® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating BT8009, a Bicycle^® Toxin Conjugate (BTC^®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist^® (Bicycle TICA^®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle^® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle^® technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228647806/en/

Investors:

Stephanie Yao

SVP, Investor Relations and Corporate Communications

ir@bicycletx.com

857-523-8544

Media:

Argot Partners

Deborah Elson

media@bicycletx.com

212-600-1902

Source: Bicycle Therapeutics plc

FAQ

When will Bicycle Therapeutics plc participate in investor conferences in March 2024?

Bicycle Therapeutics plc will participate in investor conferences in March 2024 including TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays Global Healthcare Conference.

What is the proprietary technology of Bicycle Therapeutics plc based on?

Bicycle Therapeutics plc's proprietary technology is based on bicyclic peptide technology, offering a new class of therapeutics.

Where can investors access the live webcasts of the fireside chats?

Investors can access the live webcasts of the fireside chats on the Investor section of Bicycle Therapeutics plc's website at www.bicycletherapeutics.com.

Will archived replays of the webcasts be available after the fireside chat dates?

Yes, archived replays of the webcasts will be available following the fireside chat dates for investors to access.